InflaRx N.V.
IFRX evidence brief
What we can confirm
- Market Cap:
- $268.2M
What it means
What to watch
Prepared research question
What matters most for IFRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IFRX
InflaRx N.V. (IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, with a pipeline including the oral C5aR1 inhibitor izicopan and the monoclonal antibody vilobelimab.
Key risk: Early-stage pipeline
Market Cap
$268.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 2 clinical trials for InflaRx N.V..
InflaRx N.V. (IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, with a pipeline including the oral C5aR1 inhibitor izicopan and the monoclonal antibody vilobelimab.
- InflaRx is developing izicopan (formerly INF904), an oral C5aR1 inhibitor, for conditions such as chronic spontaneous urticaria, hidradenitis suppurativa, and ANCA-associated vasculitis [news · published 2025-11-08].
- The company is assessing the feasibility of broadening its development and regulatory path for ANCA-associated vasculitis in Europe following an EMA recommendation on Tavneos [news · published 2026-06-30].
- New in vitro data indicate that izicopan does not exhibit time-dependent inhibition of CYP3A4, suggesting a lower risk for drug-drug interactions and liver toxicity [news · published 2026-04-09].
- InflaRx has initiated a Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum and a Phase 2a basket study of INF904 in chronic spontaneous urticaria and hidradenitis suppurativa [catalyst].
- The WHO granted the international nonproprietary name 'izicopan' to INF904 in December 2025 [news · published 2025-12-11].
What works
- Izicopan shows a favorable preclinical profile, including no time-dependent CYP3A4 inhibition, which may reduce drug-drug interaction and liver toxicity risks [news · published 2026-04-09].
- The company has a clear strategic focus on izicopan for ANCA-associated vasculitis and renal diseases, with ongoing Phase 2 planning [news · published 2026-05-08].
- InflaRx has multiple active clinical programs, including a Phase 3 trial for vilobelimab and a Phase 2a basket study for izicopan, indicating pipeline breadth [catalyst].
What to weigh
- The company's lead candidate, vilobelimab, has not yet achieved regulatory approval, and the Phase 3 trial in ulcerative pyoderma gangrenosum is ongoing [catalyst].
- Izicopan is still in early-stage clinical development (Phase 2a), with topline data expected but not yet reported as of the latest news [news · published 2025-11-08].
- The feasibility of expanding AAV development in Europe is still under assessment, with no confirmed regulatory path [news · published 2026-06-30].
From the filings
Quoted directly from source documents.
Izicopan does not exhibit time-dependent inhibition of CYP3A4.
“izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions (DDIs) and liver toxicity.”
News · April 9, 2026
InflaRx is assessing feasibility of broadening AAV development in Europe.
“InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and”
News · June 30, 2026
The WHO granted the INN 'izicopan' to INF904.
“the World Health Organization (WHO) has granted the international nonproprietary (generic) name (INN) of “izicopan” to the Company for its orally available C5aR inhibitor, formerly known as INF904”
News · December 11, 2025
InflaRx initiated a Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum.
“Phase3_Start: A Randomized, Double-blind, Placebo-controlled, Multicenter, Adaptive Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in the Treatment of Ulcerative Pyoderma Gangrenosum”
Catalysts · November 1, 2023
Catalyst timeline
- 2023-11-01 · Phase 3 start for vilobelimab in ulcerative pyoderma gangrenosum — A randomized, double-blind, placebo-controlled, multicenter, adaptive Phase III trial to investigate efficacy and safety of vilobelimab.
- 2025-01-02 · Phase 2a start for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa — Phase 2a open-label basket study to evaluate safety and pharmacokinetics of INF904, an oral C5aR1 inhibitor.
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — Izicopan is in Phase 2a; no pivotal data yet. Topline results expected but not reported [news · published 2025-11-08].
- Regulatory uncertainty in AAV — Feasibility of AAV development in Europe is under assessment; no clear regulatory path [news · published 2026-06-30].
- Competition in complement space — Multiple companies target complement system; differentiation of izicopan not yet proven in late-stage trials [news · published 2026-04-09].
What to watch
- Topline data from the Phase 2a trial of izicopan in hidradenitis suppurativa and chronic spontaneous urticaria, expected in November 2025 [news · published 2025-11-08].
- Regulatory interactions with EMA regarding vilobelimab and izicopan for ANCA-associated vasculitis [news · published 2026-06-30].
- Presentation of late-breaking pre-clinical data on izicopan at Kidney Week 2026 (October 21-25) [news · published 2026-10-02].
- Progress of the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum [catalyst].
Sources: Catalysts · News · Generated October 5, 2026 · How we verify sources →
Run InflaRx N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available InflaRx N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
34
Total value held
$16.7M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 7,933,910 | $7.1M |
| 683 capital management, llc | 3,315,000 | $3.0M |
| bank of america corp /de/ | 1,975,000 | $1.8M |
| eversept partners, lp | 1,758,573 | $1.6M |
| morgan stanley | 1,175,576 | $1.1M |
| marshall wace, llp | 554,364 | $493K |
| raymond james financial inc | 395,803 | $354K |
| squarepoint ops llc | 301,987 | $270K |
| t3 companies, llc | 291,014 | $260K |
| two sigma investments, lp | 189,075 | $169K |
Showing top 10 of 34 institutional holders of InflaRx N.V.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 4.1%
- Days to cover
- 7.5
- Shares short
- 2,452,174
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IFRX short interestFrequently asked questions
What is the AI investment thesis for InflaRx N.V.?
InflaRx N.V. (IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, with a pipeline including the oral C5aR1 inhibitor izicopan and the monoclonal antibody vilobelimab.
Who is the CEO of InflaRx N.V.?
Prof. Niels C. Riedemann M.D., Ph.D. is the chief executive officer of InflaRx N.V. (IFRX).
Where is InflaRx N.V. headquartered?
InflaRx N.V. (IFRX) is headquartered in Jena, Germany.
What therapeutic areas does InflaRx N.V. focus on?
InflaRx N.V. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.